fentanyl Side Effects
Also known as: Duragesic, Actiq
Analysis of 95,293 adverse event reports submitted to the FDA from 1997 to 2025.
Total Reports
95,293
Death-Related
27,119
28.5% of reports
Hospitalizations
32,091
33.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 27,119 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DRUG ABUSE | 8,949 |
| DEATH | 5,337 |
| TOXICITY TO VARIOUS AGENTS | 4,622 |
| OVERDOSE | 2,358 |
| CARDIO-RESPIRATORY ARREST | 1,526 |
| CARDIAC ARREST | 1,343 |
| DRUG DEPENDENCE | 1,259 |
| COMPLETED SUICIDE | 1,169 |
| RESPIRATORY ARREST | 874 |
| PAIN | 859 |
| RENAL FAILURE | 752 |
| PNEUMONIA | 712 |
| NAUSEA | 577 |
| MALIGNANT NEOPLASM PROGRESSION | 568 |
| SEPSIS | 568 |
| RESPIRATORY FAILURE | 558 |
| HYPOTENSION | 529 |
| DYSPNOEA | 526 |
| ANXIETY | 521 |
| VOMITING | 492 |
Reactions in Hospitalization Reports
Top reactions in 32,091 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| NAUSEA | 2,461 |
| PAIN | 2,239 |
| VOMITING | 2,084 |
| DRUG INEFFECTIVE | 1,888 |
| PNEUMONIA | 1,721 |
| DYSPNOEA | 1,697 |
| HYPOTENSION | 1,655 |
| DIARRHOEA | 1,633 |
| PYREXIA | 1,625 |
| FATIGUE | 1,608 |
| OFF LABEL USE | 1,498 |
| OVERDOSE | 1,415 |
| DRUG INTERACTION | 1,406 |
| FALL | 1,291 |
| TOXICITY TO VARIOUS AGENTS | 1,256 |
| ANAEMIA | 1,253 |
| DRUG ABUSE | 1,221 |
| ABDOMINAL PAIN | 1,196 |
| ASTHENIA | 1,159 |
| CONFUSIONAL STATE | 1,051 |
Nearby — Related Medications
What the FAERS Data Reveals About fentanyl Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 95,293 voluntary reports linked to fentanyl and its brand equivalents (Duragesic, Actiq), spanning 1997 through 2025. Of those, 27,119 (28.5%) listed death as an outcome and 32,091 (33.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 51% were female and 49% male; age distribution skews toward 45-64, with 22,231 reports in that bracket. The single most reported reaction is drug abuse with 10,453 submissions, followed by pain and drug dependence.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.